

1635



## AMENDMENT TRANSMITTAL LETTER

Docket No.  
27656/37821

Application No.  
10/018,437-Conf. #4498

Filing Date  
June 3, 2002

Examiner  
T. C. Gibbs

Art Unit  
1635

Applicant(s): Uwe Zangemeister-Wittke et al.

Invention: OLINGONUCLEOTIDE DERIVITIVES DIRECTED AGAINST HUMAN BCL-XL AND HUMAN BCL-2 mRNA

### TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

<b>CLAIMS AS AMENDED</b>					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
<b>Total Claims</b>	17	- 26 =		x	
<b>Independent Claims</b>	2	- 3 =		x	
<b>Multiple Dependent Claims (check if applicable)</b>					<input type="checkbox"/>
<b>Other fee (please specify):</b>					
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:</b>					0.00

Large Entity

Small Entity

No additional fee is required for this amendment.

Please charge Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.  
A duplicate copy of this sheet is enclosed.

A check in the amount of \$ \_\_\_\_\_ to cover the filing fee is enclosed.

Payment by credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 13-2855  
as described below. A duplicate copy of this sheet is enclosed.

Credit any overpayment.

Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.


  
\_\_\_\_\_  
Jeffrey S. Sharp  
Attorney Reg. No.: 31,879

Dated: December 30, 2004

MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 30, 2004

Signature:  (Jeffrey S. Sharp)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date shown below.

Dated: December 30, 2004

Signature:   
Jeffrey S. Sharp

Docket No.: 27656/37821  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

ZANGEMEISTER-WITTKE et al.

Application No.: 10/018,437

Filed: June 3, 2002

For: OLIGONUCLEOTIDE DERIVATIVES  
DIRECTED AGAINST HUMAN BCL-XL  
AND HUMAN BCL-2 mRNA

Group Art Unit: 16352

Examiner: Terra C. Gibbs



**RESPONSE TO RESTRICTION REQUIREMENT  
AND AMENDMENT UNDER 37 C.F.R. §1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

This is in response to the Office Action dated November 30, 2004 in which claims 1-26 were subjected to a five-way restriction requirement. In response to the request, Applicants elect Group II (claim 2). Applicants also amend claims 3, 4, 7, 8 and 26 such that each of claims 3-18 now depend from elected claim 2 and specify below further restrictions as they were applied by the Examiner against Group I.

**INTRODUCTORY COMMENTS**

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

**A Current Listing of the Claims** begins on Page 2 of this paper.

**Remarks** begin on Page 8 of this paper.